Abstract 1588P
Background
HZ infection is a potential cause of additional morbidity in immunocompromised patients (pts). ASCO, ESMO, and AIOM recommend recombinant zoster vaccine (RZV, Shingrix®, GSK) for pts who are immunocompromised due to cancer therapy. Vaccination rates among these pts remain suboptimal, and research on effective interventions to improve vaccination rates is limited. We report quality improvement interventions aimed at enhancing vaccine uptake among cancer outpatients.
Methods
A two-phase vaccination program for cancer outpatients receiving cancer treatments attending the Medical Oncology department of ASST Rhodense was conducted. Firstly, based on previous COVID-19 experience and with the collaboration of pts asociation La Lampada di Aladino ETS, a cross-sectional survey was administered to evaluate knowledge and awareness about HZ and RZV, vaccine hesitancy and the willingness of oncology pts to receive the RZV directly in the oncology department. Subsequently, an in-house vaccination program was managed by oncology staff.
Results
Two hundred pts conducted the survey while undergoing cancer treatment, highlighting partial understanding of HZ and RZV and a huge willingness to receive RZV from oncological staff. From June 2023 to April 2024, 220 pts received at least 1 dose of RZV, among which 152 (69%) received the second dose, resulting in a vaccination rate of 44% (220/496). Pts characteristics were as follows: 57% female, median age 70 (43-93) years, 80% ECOG PS 0-1, and 39% with at least 3 comorbidities. The most frequent tumors were breast 29%, lung 18%, colorectal 14%, prostate 10%, and upper GI 6%. The most common anticancer treatments were chemotherapy 44%, immunotherapy 28% targeted therapy 23%, and endocrine therapy 5%. No severe adverse event to RZV were reported. RZV was administered on average 7 (0-51) days before and 8 (0-70) days after intravenous therapy respectively.
Conclusions
Most cancer pts have a limited perception of the importance of vaccination. Vaccination with RZV was found to be safe. Our study highlights the potential for in-hospital vaccination strategies to enhance vaccination coverage and improve health outcomes among oncology pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
GSK.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1583P - Trial-level surrogacy of intermediate endpoints in adjuvant or neoadjuvant use of immune checkpoint blockade
Presenter: Luís Leite
Session: Poster session 10
1584P - Association of travel burden (TB) with colorectal cancer (CRC) outcomes in resource-limited settings (RLS)
Presenter: Saquib Banday
Session: Poster session 10
1585P - Performance status restrictions in clinical trials leading to US food and drug administration (FDA) drug approval: A cross-sectional study of a decade (2014-2023)
Presenter: Giovanni Maria Iannantuono
Session: Poster session 10
1586P - Current status of breast cancer: A comparative analysis between developed and developing countries
Presenter: Ana Isabel Martin Quesada
Session: Poster session 10
1587P - As seen through Hollywood’s lens: Cancer in movies, 2010-2020
Presenter: David Benjamin
Session: Poster session 10
1589P - Ramping up phase I trial recruitment: Defining potential barriers and disparities
Presenter: Burak Aktas
Session: Poster session 10
1590P - Prevalence and impact on survival of presentation to the emergency room of cancer patients: A retrospective study on real-life data
Presenter: Sonia Priou
Session: Poster session 10
1591P - Development and economic trends in new anticancer therapies licensed in the UK from 2020 to 2024
Presenter: Geetin Majhail
Session: Poster session 10
1592P - Awareness and interest of oncology professionals in sex and gender differences in cancer risk and outcome: Analysis of an ESMO Gender Medicine Task Force survey
Presenter: Berna C. Özdemir
Session: Poster session 10
1593P - Factors associated with multiple general practitioner consultations before cancer diagnosis in adolescents and young adults: A cohort study in Australia
Presenter: Jeremy Lewin
Session: Poster session 10